Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Mirum Pharmaceuticals Launch New Drug for Treatment of Alagille Syndrome

Mirum Pharmaceuticals has launched a novel drug Maralixibat, for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients one year of age and older.

ALGS is a rare genetic disorder within which digestive juice ducts are abnormally slim, unshapely and reduced in a range that ends up in digestive juice within the liver and ultimately progressive disease.

The multiple organ systems are also littered with the mutation, together with the heart, liver, kidneys and central nervous system, in patients with ALGS.

Maralixibat was granted breakthrough therapy designation based on evidence from the ICONIC Phase 2b clinical trial in children with ALGS.

Maralixibat is an ileal bile acid transporter inhibitor in clinical development for pediatric cholestasis, Alagille syndrome, and progressive familial intrahepatic cholestasis.

The breakthrough designation is granted by the FDA to investigational medicines supposed to treat a serious or life-threatening condition for which preliminary clinical evidence could demonstrate substantial improvement on at least one clinically significant endpoint over available therapy.

The breakthrough therapy designation is intended to expedite development and review and conveys all the fast track designation program options, including a lot of intensive federal agency interaction and guidance.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024